SCHEMBL973060

SCHEMBL973060

CC(=O)Nc1nc(C=O)cs1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.69
HSD17B10 Q99714 2/20 0.69
MAPT P10636 1/20 0.69
L3MBTL1 Q9Y468 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.54
KMT2A Q03164 1/20 0.54
ABL1 P00519 7/20 0.49
NPC1 O15118 3/20 0.49
MAPK1 P28482 1/20 0.49
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
TYR P14679 1/20 0.47
RAB9A P51151 3/20 0.46
AOC3 Q16853 1/20 0.44
PI4KB Q9UBF8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12947791 0.84 KDM4E (0.67) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4753881 0.84 MAPT (0.49) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL9834015 0.83 KDM4E (0.61) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL9834016 0.83 KDM4E (0.61) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4871143 0.81 TYR (0.50) KDM4EHSD17B10MAPTSMN1; SMN2KMT2A
SCHEMBL4883834 0.80 KDM4E (0.61) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4883820 0.80 KDM4E (0.61) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4891174 0.80 KDM4E (0.53) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4891163 0.80 KDM4E (0.53) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL16741154 0.79 SMN1; SMN2 (0.46) KDM4EHSD17B10MAPTSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-9603833-B2 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-TECH UENO, LTD. (JP) 2017-03-28 US disclosed
US-9603833-B2 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-TECH UENO, LTD. (JP) 2017-03-28 US disclosed
EP-2639229-B9 Thiazole Derivative and use thereof as VAP-1 Inhibitor R TECH UENO LTD (JP) 2015-08-05 EP disclosed
EP-2650287-B9 Thiazole Derivative and use thereof as VAP-1 Inhibitor R TECH UENO LTD (JP) 2015-08-05 EP disclosed
EP-2639229-B9 Thiazole Derivative and use thereof as VAP-1 Inhibitor R TECH UENO LTD (JP) 2015-08-05 EP disclosed
EP-2886534-A1 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-Tech Ueno, Ltd. (JP) 2015-06-24 EP disclosed
EP-2886534-A1 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-Tech Ueno, Ltd. (JP) 2015-06-24 EP disclosed
US-20150166525-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R TECH UENO LTD (JP) 2015-06-18 US disclosed
US-20150166525-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R TECH UENO LTD (JP) 2015-06-18 US disclosed
US-5378849-A Kidney vasodilators; orally administered YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1995-01-03 US disclosed
US-5204468-A Nephrovascular dilators and diuretics; side effect reduction; administered by mouth YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1993-04-20 US disclosed
WO-1993007141-A1 HETEROCYCLIC 3-PHENYLPYRROLIDIN-2-ONES, THEIR PREPARATION AND USE FOR THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING TUMOR NECROSIS FACTOR PRODUCTION SMITHKLINE BEECHAM CORPORATION (US) 1993-04-15 WO disclosed
US-5079256-A Administering to treat diseases of circulatory organs such as renal/cardiac insufficiency YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1992-01-07 US disclosed
US-5077406-A Cyclization, deprotecting and salt formation YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1991-12-31 US disclosed
EP-0224919-B1 NEW THIAZOLE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-08-14 EP disclosed
US-4966904-A DILUROGENITAL DISORDERS; DILATION OF NEOPHROVASCULAR TRACTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1990-10-30 US disclosed
US-4876261-A UROGENITAL DISORDERS; NEPHROVASCULAR DILATORS; ACT ON DOPAMINE RECEPTOR YAMANOUCHI PHARMACEUTICAL CO., LTD. 1989-10-24 US disclosed
US-4742057-A Antiallergic thiazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-05-03 US disclosed
EP-0224919-A2 New thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166525-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR VAPB, VAPA, BET1 KDM4E 1213/4885HSD17B10 2359/4885MAPT 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.